Osteonecrosis Treatment Market is expected to reach US$ 1,021.92 million by 2030

According to our new research study on “Osteonecrosis Treatment Market Size and Forecast to 2030 – Global and Regional Analysis – by Treatment Type and End User,” the osteonecrosis treatment market is expected to grow from US$ 637.18 million in 2022 to US$ 1,021.92 million by 2030; it is estimated to register a CAGR of 6.08% from 2022 to 2030. A few of the prominent factors driving the market growth include the rising cases of osteonecrosis in people owing to increasing number of road accidents, and long-term use of steroids among patients. Additionally, the rising geriatric population and growing awareness about bone health benefit the osteonecrosis treatment market. Further, the adoption of orthobiologics and regenerative therapies is likely to emerge as a future trend in the osteonecrosis treatment market during 2022–2030.

Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease that results in the death of bone cells. It happens when blood flow to bones is disrupted and worsens over time. The causes of this condition include broken bones, dislocated hips, radiation therapy, and alcohol abuse.

The osteonecrosis treatment market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). The growth of the osteonecrosis treatment market in North America is attributed to the high availability and adoption of advanced treatment options, and the concentration of key manufacturers in the region. The US, in particular, has a high adoption rate of osteonecrosis treatment procedures. The increasing geriatric population, coupled with growing awareness of the medical condition and its diagnosis, is further expected to boost the growth of the osteonecrosis treatment market in North America in the coming years.

Future Trend

Adoption of Orthobiologics and Regenerative Therapies to Emerge as Future Trend in Osteonecrosis Treatment Market

Orthoregeneration is the segment of medicine that leverages the benefits of biology to enhance healing, reduce pain, improve function, and create a favorable environment for tissue regeneration, thereby curing orthopedic conditions. Interventional orthobiologics, whose functioning is based on the principles of Orthoregeneration, are revolutionizing the field of orthopedic medicine. Orthobiologics are derived from a patient's tissues such as bone marrow or blood. They consist of signaling molecules or cells that stimulate the healing of musculoskeletal injuries.

Regenerative treatments such as stem cell therapy, platelet-rich plasma therapy, growth factors, and tissue engineering are being studied and assessed in clinical trials to optimize treatment outcomes. In an article published by PubMed Central in January 2023, a study was carried out to evaluate the use of biologics in treating bilateral AVN of the femoral head in a 44-year-old male suffering from the condition. The patient received bone marrow aspirate concentrate (BMAC) in the right femoral head and adult autologous live cultured osteoblasts in the left femoral head, after which, he was asked to pay follow-up visits for several years. The study concluded that biological therapy using differentiated osteoblasts is a viable option for AVN femoral head compared to an undifferentiated BMAC cocktail.

Key players in the osteonecrosis treatment market are engaged in the R&D of innovative treatments, along with the launch of products. In February 2021, Additive Orthopedics, LLC, received US Food and Drug Administration (FDA) approval for its first patient-specific talus spacer, which is also the world’s first humanitarian-use implant. Similarly, Arthrex, a leading global medical device company, is now offering IntraOsseous BioPlasty (IOBP) technique for spontaneous osteonecrosis of the knee (SONK). This technique involves performing a core decompression of the lesion followed by the direct application of concentrated bone marrow aspirate, which is prepared using the Angel concentrated platelet-rich plasma (cPRP) system.

Treatment Type – Overview

Based on treatment type, the osteonecrosis treatment market is segmented into drugs and surgeries. The drugs segment held the largest market share in 2022. However, surgeries segment is anticipated to grow with the highest CAGR of 7.63%.

End User – Overview

In terms of end user, the osteonecrosis treatment market is categorized into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment is expected to record the highest CAGR in the market during 2022–2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the stage and severity of the disease, they provide a variety of treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.

Osteonecrosis Treatment Market: Competitive Landscape and Key Developments

Major players in the osteonecrosis treatment market include Novartis AG; Teva Pharmaceutical Industries Ltd.; Zimmer Biomet; Pfizer Inc; Stryker; Exactech Inc; Merck Co Inc; Dr. Reddy’s Laboratories Ltd; Viatris Inc; and Horizon Therapeutics plc. These leading players adopt strategies such as the launch of new products, expansion and diversification of market presence, and expansion of new customer base, in turn, tapping prevailing business opportunities.

A few of the inorganic strategies implemented by players in the osteonecrosis treatment market are mentioned below:

• In May 2022, Regrow Biosciences received an Orphan Drug Designation (ODD) for OSSGROW from the USFDA as well as the European Medicines Agency (EMA). The drug is intended for patients who are suffering from osteonecrosis.
• In April 2021, ECI Pharmaceuticals LLC signed an exclusive distribution agreement with AiPing Pharmaceuticals, Inc. The agreement enabled AiPing to handle the sales, marketing, and distribution of ibuprofen 400 mg, 600 mg, 800 mg tablets, and folic Acid 1 mg tablets in the US.
• In February 2021, Additive Orthopaedics received FDA approval for the total talus replacement implant designed as a humanitarian-use device for the talus spacer for the patient-specific treatment of avascular necrosis of the talus in the US.  

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com